Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial

scientific article published in March 2003

Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2362.2003.01135.X
P698PubMed publication ID12641538

P50authorCasper G. SchalkwijkQ76998834
P2093author name stringvan den Berg M
Twisk JW
Stehouwer CD
Rauwerda JA
de Jong SC
Vermeulen EG
P2860cites workSerum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn StudyQ57830035
Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn studyQ28141937
Homocysteine and cardiovascular diseaseQ28265188
Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion moleculesQ28365442
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy menQ29619308
Endogenous tissue-type plasminogen activator and risk of myocardial infarctionQ41079493
Endothelial dysfunction and pathogenesis of diabetic angiopathyQ41526683
Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes SurveyQ41914147
Features of endothelial dysfunction in early diabetic nephropathyQ42494570
Association between albumin:creatinine ratio and 24-hour ambulatory blood pressure in essential hypertensionQ43596946
Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.Q50926553
Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.Q50970547
Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.Q51558185
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakesQ56171250
P433issue3
P921main subjectendotheliumQ111140
folic acidQ127060
vitamin BQ183206
pyridoxineQ423746
vitamin B6Q205130
P304page(s)209-215
P577publication date2003-03-01
P1433published inEuropean Journal of Clinical InvestigationQ15745208
P1476titleHomocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial
P478volume33

Reverse relations

cites work (P2860)
Q37452734Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas
Q35600418Does homocysteine cause hypertension?
Q55499367Effect of Combined Treatment With Folic Acid, Vitamin B6, and Vitamin B12 on Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Women.
Q59150479Homocysteine and vitamin B12 concentrations and mortality rates in type 2 diabetes
Q36273319Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
Q33727314Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort
Q83193282No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease
Q35830086Nutrition and prevention of ischemic stroke: present knowledge, limitations and future perspectives
Q93161742Telomere length, vitamin B12 and mortality in persons undergoing coronary angiography: the Ludwigshafen risk and cardiovascular health study

Search more.